|
Malignant neoplasm of liver
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Western blot analysis showed high CPA4 expression in the liver cancer cell line Bel7402 and low expression in HepG2 cells.
|
31058377 |
2019 |
|
Malignant neoplasm of liver
|
0.020 |
Biomarker
|
disease |
BEFREE |
Multivariate Cox regression model showed that CPA4 was an independent prognostic factor for patients with liver cancer.
|
28123604 |
2017 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
However, the role of CPA4 in lung tumorigenesis remains unclear.
|
31397502 |
2019 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Subcutaneous tumorigenesis was performed in nude mice to confirm the tumor-promoting effects of CPA4 in vivo.
|
31279884 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
We conclude that CPA4 is diagnostically and prognostically not futile when used in combination with the other considerations and measurements in breast cancer.
|
30875843 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Using whole transcriptome analysis and a lentiviral short hairpin RNA screening library, carboxypeptidase A4 (CPA4) was identified as a novel marker in breast cancer and a therapeutic target in triple‑negative breast cancer (TNBC) in the present study.
|
30628666 |
2019 |
|
Prostate Cancer, Hereditary, 7
|
0.020 |
Biomarker
|
disease |
BEFREE |
Carboxypeptidase 4 (CPA4) is a zinc-dependent metallocarboxypeptidase on chromosome 7q32 in a region linked to prostate cancer aggressiveness.
|
19245716 |
2009 |
|
Prostate Cancer, Hereditary, 7
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings support that CPA4 is imprinted and may become a strong candidate gene for prostate cancer-aggressiveness.
|
12552318 |
2003 |
|
anaphylaxis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
There has been an interest in the detection of newer biomarkers in anaphylaxis including platelet activation factor (PAF), chymase, carboxypeptidase A3, dipeptidyl peptidase I (DPPI), basogranulin, and CCL-2.
|
31024519 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Consistent with these observations, we generated xenograft tumor models to confirm that CPA4 downregulation suppressed NSCLC cell growth.
|
31397502 |
2019 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Accordingly, CPA4 promotes CRC cell growth via activating the STAT3 and ERK pathways and may be a prognostic factor or therapeutic target for CRC.
|
31279884 |
2019 |
|
Coronary Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mast cell derived carboxypeptidase A3 is decreased among patients with advanced coronary artery disease.
|
29512095 |
2019 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mast cell derived carboxypeptidase A3 is decreased among patients with advanced coronary artery disease.
|
29512095 |
2019 |
|
Cystic Fibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Interestingly, p.Tyr263Cys tend to be more frequently observed in CF patients with CPA than in patients without CPA (4/68 vs 0/35), and DCTN4 missense variants tend to be more frequent in male CF patients with CPA bearing two class II mutations than in male CF patients without CPA bearing two class II mutations (P = 0.06).
|
25763772 |
2016 |
|
Fetal Growth Retardation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
As CPA4 has a potential role in cell proliferation and differentiation, two preferentially expressed copies in mUPD patients with SRS syndrome would result in excess expression and could alter the growth profiles of these subjects and give rise to intrauterine growth restriction.
|
12676894 |
2003 |
|
Glioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The circCPA4/let-7/CPA4 axis regulates glioma progression by ceRNA mechanism, and circCPA4 could be a novel prognostic biomarker and target for glioma treatment.
|
31424161 |
2019 |
|
Hepatitis
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This study aimed to evaluate the expression of carboxypeptidase 4 (CPA4) in hepatitis, liver cirrhosis and liver cancer tissues, and revealed its clinical significance in liver cancer progression.
|
28123604 |
2017 |
|
Hepatitis A
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to evaluate the expression of carboxypeptidase 4 (CPA4) in hepatitis, liver cirrhosis and liver cancer tissues, and revealed its clinical significance in liver cancer progression.
|
28123604 |
2017 |
|
Mastocytosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Herein we have identified local mastocytosis and mast cell degranulation in the esophagi of patients with EE; identified an esophageal mast cell-associated transcriptome that is significantly divergent from the eosinophil-associated transcriptome, with carboxypeptidase A3 mRNA levels serving as the best mast cell surrogate marker; and provided evidence for the involvement of KIT ligand in the pathogenesis of EE.
|
20538331 |
2010 |
|
melanoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The combined action of mast cell chymase, tryptase and carboxypeptidase A3 protects against melanoma colonization of the lung.
|
28212574 |
2017 |
|
Myocardial Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of the study was to assess if serum concentration of MC proteases: carboxypeptidase A3, cathepsin G and chymase 1 is associated with the extension of CAD and MI.
|
29512095 |
2019 |
|
Nasal Polyps
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The mast cells detected in the epithelium in NPs were characterized by the expression of tryptase and carboxypeptidase A3 but not chymase.
|
22534535 |
2012 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Recent research focused on prolonged survival has suggested that carboxypeptidase A4 (CPA4) plays a role in both tumor microenvironment formation and distant metastasis in cancer.
|
30875843 |
2019 |
|
Pulmonary Eosinophilia
|
0.010 |
Biomarker
|
disease |
BEFREE |
A signature of 6 genes, including Charcot-Leydon crystal protein (CLC); carboxypeptidase A3 (CPA3); deoxyribonuclease I-like 3 (DNASE1L3); IL-1β (IL1B); alkaline phosphatase, tissue-nonspecific isozyme (ALPL); and chemokine (C-X-C motif) receptor 2 (CXCR2), was reproducible and could significantly (P < .0001) discriminate eosinophilic asthma from other phenotypes, including patients with noneosinophilic asthma (AUC, 89.6%), paucigranulocytic asthma (AUC, 92.6%), or neutrophilic asthma (AUC, 91.4%) and healthy control subjects (AUC, 97.6%), as well as discriminating patients with neutrophilic asthma from those with paucigranulocytic asthma (AUC, 85.7%) and healthy control subjects (AUC, 90.8).
|
24582314 |
2014 |
|
Tumor Progression
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Carboxypeptidase A4 (CPA4), a member of the metallo-carboxypeptidase family, is overexpressed in liver cancer and is associated with cancer progression.
|
31058377 |
2019 |